Vicore Pharma Holding AB Sponsored ADR stock analysis
Vicore Pharma Holding AB Sponsored ADR (VCRE) Stock Price & Analysis
VCRE Stock Chart & Stats
- Day’s Range
- $10.12 - $10.25
- 52-Week Range
- $7.88 - $17.80
- Previous Close
- $10.16
- Volume
- N/A
- Average Volume (3M)
- 21.41K
- Market Cap
- $286.88M
- Enterprise Value
- $190.38M
- Total Cash (Recent Filing)
- $771.99M
- Total Debt (Recent Filing)
- $0
- Price to Earnings (P/E)
- ―
- Beta
- 0.55
- Next Earnings
- Feb 25, 2027 (Est.)
- EPS Estimate
- -0.53
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Vicore Pharma Holding AB Sponsored ADR News
VCRE FAQ
What was Vicore Pharma Holding AB Sponsored ADR’s price range in the past 12 months?
What is Vicore Pharma Holding AB Sponsored ADR’s market cap?
When is Vicore Pharma Holding AB Sponsored ADR’s upcoming earnings report date?
How were Vicore Pharma Holding AB Sponsored ADR’s earnings last quarter?
Is Vicore Pharma Holding AB Sponsored ADR overvalued?
Does Vicore Pharma Holding AB Sponsored ADR pay dividends?
What is Vicore Pharma Holding AB Sponsored ADR’s EPS estimate?
How many shares outstanding does Vicore Pharma Holding AB Sponsored ADR have?
What happened to Vicore Pharma Holding AB Sponsored ADR’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Vicore Pharma Holding AB Sponsored ADR?
What is the TipRanks Smart Score and how is it calculated?
Vicore Pharma Holding AB Sponsored ADR Stock Smart Score
Company Description
Vicore Pharma Holding AB Sponsored ADR
Vicore Pharma Holding AB (publ), a Gothenburg, Sweden-based company, specializes in the discovery and advancement of therapies for rare lung conditions. Its core pipeline features VP01, an orally administered small molecule currently in Phase II clinical trials for indications such as interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19. The company is also progressing VP02, a novel formulation and delivery approach for an established immunomodulatory compound, which is in preclinical development for treating IPF. Vicore maintains strategic alliances, including a development cooperation with Emeriti Bio AB, a licensing arrangement with Nanologica AB (publ), and a collaboration with Alex Therapeutics AB focused on creating and clinically validating a digital therapeutic (DTx) built on the Alex DTx platform. Established in 2000, the company was formerly known as Mintage Scientific AB.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Ahmed S. Mousa
- Employees
- 37
- Website
- www.vicorepharma.com
- Address
- Kornhamnstorg 53, Stockholm, AB, 111 27, SE
Vicore Pharma Holding AB Sponsored ADR (VCRE) Earnings & Revenues
VCRE Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 6 | 8 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 2 | 0 | 6 |




